May 8, 2020 / 11:37 AM / 19 days ago

BRIEF-Shanghai Henlius Biotech Says Application Injection HLX56 Approved In Taiwan

May 8 (Reuters) - Shanghai Henlius Biotech Inc:

* APPLICATION FOR CLINICAL TRIAL OF ANTI-DEATH RECEPTOR 4 MONOCLONAL ANTIBODY INJECTION HLX56 APPROVED IN TAIWAN Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below